Table 1.

Experimentally validated targets of miR-146a in lung cancer.

	Molecular Target	Clinical Significance	References
miR-146a	COX2	Decreases basal prostaglandins	[35]
	Cyclin D1, Cyclin D2	Discourages cell proliferation	[63]
	IRS2	Discourages EMT/cancer progression	[65]
	IL-6, IL-8, RANTES	Prevents cytokine overproduction	[73,101]
	IRAK1, TRAF6, NF-kB	Weakens TNFα inflammatory stimuli and promotes cisplatin sensitivity	[72,101]
	Cyclin J	Promotes cisplatin chemosensitivity	[64]

COX (Cyclooxygenase); IRS2 (Insulin Receptor Substrate 2); IL (Interleukins); RANTES (Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted); IRAK1 (Interleukin 1 Receptor Associated Kinase 1); TRAF6 (Tumor necrosis factor receptor associated factor 6); NF-κB (Nuclear factor kappa B).